Experimental drug combo aims to shrink aggressive breast tumors before surgery

NCT ID NCT06353997

Recruiting now Disease control Sponsor: Providence Health & Services Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults whose tumors are measurable by ultrasound. The main goal is to see if the combination reduces breast tumor volume by more than 30% after two treatment cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INBRX-106 (an experimental immunotherapy that activates OX40 receptors on immune cells) combined with pembrolizumab (Keytruda, an approved immunotherapy)
What this could lead to: If successful, this combination could shrink tumors before standard treatment, potentially improving outcomes for people with triple-negative breast cancer.
What could go wrong: This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The combination may cause immune-related side effects or fail to improve response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ellison Institute of Technology (EITM)
RECRUITING

Los Angeles, California, 90064, United States
Providence Portland Cancer Institute - Franz Clinic
RECRUITING

Portland, Oregon, 97213, United States

Contact Email: •••••@•••••
Providence St. Vincent Medical Center
RECRUITING

Portland, Oregon, 97225, United States

Contact Email: •••••@•••••
Swedish Cancer Institute
NOT_YET_RECRUITING

Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.